Carboplatin and Nonpegylated Liposomal Doxorubicin in Primary Advanced or Recurrent Endometrial Cancer: A Phase 2 Trial Conducted by AGO Austria. Issue 2 (1st February 2015)

• Record Type: Journal Article
• Authors: Volgger, Birgit; Zeimet, Alain G.; Reinthaller, Alexander; Petru, Edgar; Schauer, Christian; Klein, Michaela; Sevelda-Schwarzgruber, Ursula; Bogner, Gerhard; Wolfram, Gerhard; Marth, Christian
• Is Part Of: International journal of gynecological cancer. Volume 25:Issue 2(2015:Feb.)
• Page Start: 257
• Page End: 262
• Publication Date: 2015-02-01
• Subjects: Advanced endometrial cancer -- Chemotherapy -- Carboplatin -- Nonpegylated liposomal doxorubicin; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000000352
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: Recurrent/advanced endometrial carcinoma carries a poor prognosis. Chemotherapy usually consists of cisplatin/doxorubicin and paclitaxel or the doublet of carboplatin and paclitaxel. We report on final results of the Austrian phase 2 AGO trial of nonpegylated doxorubicin citrate and carboplatin in 39 patients with primary advanced or relapsed endometrial cancer. The main primary end point is response rate, and the main secondary end point is feasibility. Methods: Thirty-nine patients received 60 mg/m 2 nonpegylated doxorubicin citrate and carboplatin (area under the curve, 5) every 3 weeks for 6 to 9 cycles or until progression. Best response during therapy, progression-free survival, and the toxicity profile were recorded. Results: Thirteen patients (33%) had primary advanced disease, and 26 patients (67%) had recurrent disease. Seventy-five percent of the tumors were adenocarcinomas, 15% were serous carcinomas, and 5% were clear cell and mixed müllerian carcinomas. We observed 1 complete response (3%) and 16 partial responses (41%) in the intention-to-treat population. The median progression-free survival was 7.2 months, and the median overall survival was 14.7 months. Overall, 177 cycles were administered; the mean number of cycles per patient was 4.5. Ten percent of patients received 9 cycles of chemotherapy, and 44% of patients received 6 cycles of chemotherapy. Grade 3/4 neutropenia occurred in 17%, grade 3/4 anemia in 5%, and grade 3/4 thrombopenia in 12% of the cycles. In 6% of the cycles, febrile neutropenia was noticed. Grade 3/4 nausea was seen in 5% of cycles. One patient (3%) experienced cardiac toxicity and had a reduction in the left ventricular ejection fraction to below 50%. Conclusions: The reported combination demonstrates considerable activity and should be evaluated further.